Category - Developments

Developments

FibroGen flunks Phase 3 anemia study

FibroGen’s (NASDAQ:FGEN) Phase 3 MATTERHORN study of roxadustat for treatment of anemia in patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint. The...

May 5, 2023

Developments

MindBio Therapeutics lists on CSE

MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) has listed its common shares on the Canadian Securities Exchange under the ticker symbol, MBIO. MindBio is the only company in the world to have clinical trials approved...

May 5, 2023

Developments

SAB presents positive Phase 1, 2a data in influenza

SAB Biotherapeutics (NASDAQ:SABS) presented positive safety and efficacy data from Phase 1 and 2a clinical trials of its influenza immunotherapy, SAB-176, at the AVG conference, which is hosted by the International...

May 4, 2023

Developments

Immunic posts positive Phase 1b results in celiac disease

Immunic (NASDAQ:IMUX) announced positive results from the part C portion of its Phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof...

May 4, 2023

Developments

Magenta, Dianthus in merger agreement

Magenta Therapeutics (NASDAQ:MGTA) and closely-held Dianthus Therapeutics entered into a definitive merger agreement to combine the companies in an all-stock transaction that is expected to close in the third quarter of...

May 3, 2023

Developments

NeuroSense posts positive preliminary PD biomarker data

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive preliminary results from a novel biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment of Parkinson’s...

May 2, 2023

Developments

Profound Medical’s TULSA procedure featured at AUA

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...

May 1, 2023

Developments

Kiora RP treatment seen restoring visual function in blind patients

Kiora Pharmaceuticals (NASDAQ:KPRX) presented preliminary results from an ongoing clinical trial, showing that its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind...

April 28, 2023

Developments

Avidity posts positive Phase 1/2 topline data in myotonic dystrophy 1

Avidity Biosciences (NASDAQ:RNA) reported positive topline data from the Phase 1/2 MARINA clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal...

April 28, 2023

Developments

SAB posts positive Phase 3 results in high-risk COVID-19 patients

SAB Biotherapeutics (NASDAQ:SABS) reported positive top-line results from the Phase 3 National Institutes of Health’s ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at...

April 26, 2023

Category - Developments

Subscribe